Travere Therapeutics Inc. (TVTX)
NASDAQ: TVTX
· Real-Time Price · USD
14.49
-0.45 (-3.01%)
At close: Jun 13, 2025, 3:59 PM
14.50
0.07%
After-hours: Jun 13, 2025, 04:20 PM EDT
-3.01% (1D)
| Bid | 14.25 |
| Market Cap | 1.29B |
| Revenue (ttm) | 273.53M |
| Net Income (ttm) | -226.71M |
| EPS (ttm) | -2.78 |
| PE Ratio (ttm) | -5.21 |
| Forward PE | 29.89 |
| Analyst | Buy |
| Ask | 14.5 |
| Volume | 1,307,685 |
| Avg. Volume (20D) | 1,788,322 |
| Open | 14.46 |
| Previous Close | 14.94 |
| Day's Range | 14.37 - 14.93 |
| 52-Week Range | 6.80 - 25.29 |
| Beta | 0.74 |
About TVTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TVTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TVTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-20.57%
Travere Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
1 month ago
+0.28%
Travere Therapeutics shares are trading lower. The company announced that the FDA accepted its supplemental New Drug Application for traditional approval of FILSPARI for the treatment of focal segmental glomerulosclerosis.
